Jump to content


Biomarker for Diffuse Scleroderma skin has been discovered!


Photo

Association between Initial Oral Therapy and Outcomes in Systemic Sclerosis-related Pulmonary Arterial Hypertension (SSc-PAH): Observations from PHAROS.

pharos

  • Please log in to reply
No replies to this topic

#1 Joelf

Joelf

    Star Ruby Member

  • ISN Root Admin
  • PipPipPipPipPipPipPipPipPipPipPipPipPip
  • 4,610 posts
  • Location:West Sussex

Posted 02 January 2016 - 05:20 AM

Association between Initial Oral Therapy and Outcomes in Systemic Sclerosis-related Pulmonary Arterial Hypertension (SSc-PAH): Observations from PHAROS.

 

Compared to phosphodiesterase-5 inhibitor (PDE5i) or combination endothelin-receptor antagonist (ERA)/PDE5i, initial therapy with an ERA in SSc-PAH patients was associated with a significantly worse time to clinical worsening. PubMed, Arthritis Rheumatol, 10/19/2015. (Also see PHAROS)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.


Jo Frowde
ISN Assistant Webmaster

SD World Webmaster
ISN Sclero Forums Manager
ISN News Manager

ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)